Jf. Czachura et K. Rasmussen, Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat, N-S ARCH PH, 362(3), 2000, pp. 266-275
The gradual recovery of activity of serotonergic neurons following an initi
al inhibition has been hypothesized to play an important role in the delaye
d onset of efficacy of selective serotonin reuptake inhibitors. This study
explored the clinical relevance of this hypothesis by examining the effects
of different doses and routes of administration of fluoxetine on the recov
ery of activity of serotonergic neurons over the course of a 21-day exposur
e. Single-unit, extracellular recordings of serotonergic neurons were made
in the dorsal raphe nucleus of anesthetized male rats. Acute i.v., s.c. and
i.p. administration of fluoxetine inhibited the activity of serotonergic n
eurons. With chronic administration of fluoxetine, at clinically relevant d
oses, the activity of serotonergic neurons gradually recovered to baseline
levels over the course of 14-21 days. The dose of fluoxetine (5, 10 or 20 m
g/kg per day) did not make a significant difference in the time course of t
he recovery of activity of serotonergic neurons. A significant, non-paralle
l shift in the dose-response curve of serotonergic neurons to the serotonin
-1A (5-HT1A) agonist 8-OH-DPAT occurred over the 21 days of treatment with
fluoxetine, indicating a desensitization of the 5-HT1A receptor during this
period. The recovery of firing did nit correlate with either plasma or cer
ebrospinal fluid levels of fluoxetine or norfluoxetine. These results indic
ate that, similar to the effects of dose on the speed of onset of the clini
cal effects of SSRIs, increasing the dose of fluoxetine does not hasten the
recovery of firing of serotonergic neurons during chronic administration.
These results support the hypothesis that desensitization of the 5-HT1A rec
eptor and consequent recovery of firing of 5-HT cells in the dorsal raphe n
ucleus plays a role in the delayed therapeutic onset of fluoxetine.